Compare Anheuser-Busch Inbev SA (BUD) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Cassava Sciences Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.97 (market cap $159.01B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Anheuser-Busch Inbev SA is far larger — about 3330.1× Cassava Sciences Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BUD | FLNA | |
|---|---|---|
Market Cap | $159.01B | $47.75M |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $4.64 |
52-Week Low | $57.93 | $0.87 |
Enterprise Value | $223.42B | -$34.93M |
Dividend Yield | 1.67% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
